Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Part of paid clinical trials in Burlington, Vermont.

Sponsor
University of Vermont Medical Center
Study ID
NCT05603715
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pyridostigmine Bromide — DRUG
    Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks

Study Details

Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.

Key Dates

Start date
Aug 10, 2022
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
16 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Pyridostigmine Bromide
    Open Label

Primary Outcome Measure

Change in number of spontaneous bowel movements per week after the study intervention [ Time Frame: 13-15 Weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Vermont Medical CenterBurlingtonVermont05401
Kaysi Herrera Pujols
[email protected]
802-847-4589
Lisa Deuel, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Burlington, VT

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
University of Vermont Medical Center· Burlington, VT

Related Studies